Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE 17 March 2011 at 4.00 p.m.

Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

Biotie Therapies Corp. ("Company" or "Biotie") has gained knowledge of a
notification regarding changes in holdings in accordance with Chapter 2, Section
9 of the Finnish Securities Markets Act, described below.

The notification received by the Company concerns the changes in holdings of
Versant Ventures III LLC (through Versant Venture Capital III LP and Versant
Side Fund III LP).

The mentioned change in holdings is related to the private placement of shares
(the "Offering") described in more detail in a stock exchange release issued on
11.3.2011. In the Offering a total of 35,230,000 newly issued and 14,747,084
treasury shares were offered to Finnish and international institutional and
strategic investors.

According to the notification received by the Company, the resulting holdings of
shares and votes in the Company of Versant Ventures III LLC (through Versant
Side Fund III LP and Versant Venture Capital III LP) after the conveyance of
treasury shares and registration with the Finnish Trade Register of the new
shares issued will be as follows:

Name           Number of     Number of     Number of     Share of    Share of
               shares before voting rights shares and    share       voting
               the Offering  before the    voting rights capital     rights
                             Offering      after the     after the   after the
                                           Offering      Offering    Offering
                                                         (%)         (%)

Versant Side   201,237       201,237        201,237      0.05        0.05
Fund III LP
(controlled by
Versant
Ventures III
LLC)

Versant        34,067,104    34,067,104    34,067,104    8.79        9.14
Venture
Capital III LP
(controlled by
Versant
Ventures III
LLC)

Versant        34,268,341    34,268,341    34,268,341    8.84        9.19
Ventures III
LLC (through
Versant Side
Fund III LP
and Versant
Venture
Capital III
LP) in total



The number of voting rights and percentages presented above are calculated based
on number of shares and voting rights after the conveyance of the treasury
shares and registration of the new shares with the Finnish Trade Register taking
into account the treasury shares held by the Company or its group companies
after the conveyance of the treasury shares and registration of the new shares.

On the date hereof, the registered number of shares in Biotie is 352,364,457. Of
these shares 29,659,239 are held by the Company or its group companies and the
number of outstanding shares and voting rights attached to the shares thus
amounts to 322,705,218. Subsequent to the registration of the new shares issued
in the Offering, the aggregate number of Biotie shares will be 387,594,457. Of
these shares, 14,912,155 will be held by the Company or its group companies.



Turku, 17 March 2011

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail:virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com




[HUG#1497771]